Tag: Vaxent


Streptococcus Vaccine Developed by UTHSC Professor of Medicine James B. Dale to Begin Clinical Trial

|

The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a national Centre of Excellence for Commercialization and Research (CECR) located at the University of Saskatchewan, and Vaxent in Memphis, Tennessee, are pleased to announce the initiation of a Phase 1 clinical trial of StreptAnova®, a vaccine designed to prevent Group A streptococcal (GAS) infections. The trial will be… Read More